MCID: ALC009
MIFTS: 53

Alcoholic Liver Cirrhosis

Categories: Endocrine diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Alcoholic Liver Cirrhosis

MalaCards integrated aliases for Alcoholic Liver Cirrhosis:

Name: Alcoholic Liver Cirrhosis 12 74 15 37 17
Alcoholic Cirrhosis 12 54 15
Portal Cirrhosis 12 54 71
Alcoholic Cirrhosis of Liver 12 32
Liver Cirrhosis, Alcoholic 43 71
Laennec's Cirrhosis, Alcoholic 12
Laennec's Cirrhosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:14018
ICD9CM 34 571.2
MeSH 43 D008104
NCIt 49 C34782
SNOMED-CT 67 75393009
ICD10 32 K70.3
UMLS 71 C0023891 C1622502

Summaries for Alcoholic Liver Cirrhosis

MalaCards based summary : Alcoholic Liver Cirrhosis, also known as alcoholic cirrhosis, is related to varicose veins and peritonitis, and has symptoms including icterus An important gene associated with Alcoholic Liver Cirrhosis is ADH1B (Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide), and among its related pathways/superpathways are Cytochrome P450 - arranged by substrate type and Drug metabolism - cytochrome P450. The drugs Losartan and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include Liver, bone and skin, and related phenotypes are homeostasis/metabolism and liver/biliary system

Wikipedia : 74 Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis, is a condition in which the liver does... more...

Related Diseases for Alcoholic Liver Cirrhosis

Diseases related to Alcoholic Liver Cirrhosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 493)
# Related Disease Score Top Affiliating Genes
1 varicose veins 31.4 TNF F2 CXCL8
2 peritonitis 31.0 TNF F2 CXCL8 ALB
3 alcoholic cardiomyopathy 30.8 CYP2E1 ALDH2 ADH1B
4 alcoholic pancreatitis 30.8 GSTM1 CYP2E1 ALDH2 ADH1C ADH1B
5 antipyrine metabolism 30.7 F2 ALB
6 pancreatitis 30.6 TNF SLC17A5 ALDH2 ADH1C ADH1B
7 rosacea 30.5 TNF GSTM1 CXCL8
8 pericarditis 30.4 TNF CXCL8 ALB
9 uremia 30.4 TNF ALB AHSG
10 gastric ulcer 30.4 TNF HGF CXCL8
11 amebiasis 30.4 TNF CXCL8 ALB
12 hepatorenal syndrome 30.4 GPT F2 ALB
13 endocarditis 30.3 TNF F2 CXCL8 ALB
14 peptic ulcer disease 30.2 TNF CXCL8 ALB
15 proteasome-associated autoinflammatory syndrome 1 30.2 TNF CXCL8 ALB
16 pulmonary disease, chronic obstructive 30.2 TNF GSTM1 CYP2E1 CXCL8 ALB
17 esophageal varix 30.1 GPT F2 ALB AFP
18 pulmonary edema 30.1 TNF HGF F2 CXCL8
19 gastroenteritis 30.0 TNF CXCL8 ALB
20 nutritional deficiency disease 30.0 TF F2 ALB
21 aplastic anemia 30.0 TNF GSTM1 CYP2E1 CXCL8 ALDH2 ALB
22 portal hypertension 30.0 TNF PNPLA3 GPT F2 CXCL8 ALB
23 hepatic coma 29.9 GPT F2 ALB AFP
24 hepatic encephalopathy 29.9 TNF SLC17A5 GPT F2 ALB
25 cholecystitis 29.8 GPT F2 ALB
26 aspiration pneumonia 29.8 GPT F2 ALB
27 cholestasis 29.7 SLC17A5 GPT F2 ALB
28 non-alcoholic steatohepatitis 29.7 TNF SLC17A5 GPT
29 osteoporosis 29.6 TNF SOD2 HGF CXCL8 ALB AHSG
30 cholangitis, primary sclerosing 29.6 TNF GPT F2 ALB
31 hypersplenism 29.6 GPT F2 ALB
32 acute pancreatitis 29.6 TNF GPT CXCL8 ALB
33 acute kidney failure 29.6 HGF GPT F2 ALB
34 disseminated intravascular coagulation 29.6 TNF GPT F2
35 fatty liver disease, nonalcoholic 1 29.6 SLC17A5 PNPLA3 GPT
36 pericardial effusion 29.6 GPT F2 ALB
37 esophageal cancer 29.6 TNF HGF GSTM1 CXCL8 ALDH2 ALB
38 primary biliary cirrhosis 29.5 TNF SLC17A5 GPT F2 ALB
39 alcohol dependence 29.5 SLC17A5 GPT CYP2E1 ALDH2 AKR1A1 ADH4
40 protein-energy malnutrition 29.5 TNF TF GPT ALB
41 diarrhea 29.5 TNF GPT CXCL8 ALB
42 schistosomiasis 29.5 TNF GSTM1 GPT F2 ALB
43 hepatitis e 29.4 TNF GPT F2 ALB
44 bilirubin metabolic disorder 29.4 SLC17A5 GPT F2 ALB
45 substance abuse 29.4 TF GPT CYP2E1 ALDH2 ADH1B
46 thrombocytopenia 29.4 TNF GPT F2 CXCL8 ALB
47 sclerosing cholangitis 29.4 TNF GPT F2 CXCL8 ALB
48 pneumonia 29.4 TNF GPT F2 CXCL8 ALB
49 respiratory failure 29.4 TNF GPT F2 CXCL8 ALB
50 alcohol use disorder 29.4 TF SLC17A5 GPT CYP2E1 ALDH2 ALB

Comorbidity relations with Alcoholic Liver Cirrhosis via Phenotypic Disease Network (PDN): (show all 24)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Acute Pancreatitis Alcoholic Cardiomyopathy
Alcoholic Gastritis Alcoholic Hepatitis
Alcoholic Neuropathy Chronic Congestive Splenomegaly
Deficiency Anemia Esophageal Varix
Familial Atrial Fibrillation Fatty Liver Disease
Heart Disease Hepatic Encephalopathy
Hepatocellular Carcinoma Hepatorenal Syndrome
Hypersplenism Iron Deficiency Anemia
Portal Hypertension Protein-Energy Malnutrition
Respiratory Failure Urea Cycle Disorder

Graphical network of the top 20 diseases related to Alcoholic Liver Cirrhosis:



Diseases related to Alcoholic Liver Cirrhosis

Symptoms & Phenotypes for Alcoholic Liver Cirrhosis

UMLS symptoms related to Alcoholic Liver Cirrhosis:


icterus

MGI Mouse Phenotypes related to Alcoholic Liver Cirrhosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.77 ADH1C AFP AHSG AKR1A1 ALB ALDH2
2 liver/biliary system MP:0005370 9.23 AFP ALB ALDH2 CYP2E1 HGF PNPLA3

Drugs & Therapeutics for Alcoholic Liver Cirrhosis

Drugs for Alcoholic Liver Cirrhosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Losartan Approved Phase 4 114798-26-4 3961
2
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
3
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
4
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
5
Propranolol Approved, Investigational Phase 4 525-66-6 4946
6
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
7
Valine Approved, Nutraceutical Phase 4 72-18-4 6287
8 Angiotensin Receptor Antagonists Phase 4
9 Angiotensin II Type 1 Receptor Blockers Phase 4
10 Giapreza Phase 4
11 Angiotensinogen Phase 4
12 Liver Extracts Phase 4
13 Protein Kinase Inhibitors Phase 4
14 Anti-Arrhythmia Agents Phase 4
15 Adrenergic beta-Antagonists Phase 4
16 Adrenergic Antagonists Phase 4
17 Antihypertensive Agents Phase 4
18 Mineralocorticoids Phase 4
19 Hormone Antagonists Phase 4
20 Mineralocorticoid Receptor Antagonists Phase 4
21 Natriuretic Agents Phase 4
22 Adrenergic Agents Phase 4
23 Diuretics, Potassium Sparing Phase 4
24 Vasodilator Agents Phase 4
25 diuretics Phase 4
26 Hormones Phase 4
27
Isoleucine Investigational, Nutraceutical Phase 4 73-32-5, 443-79-8 6306
28
Leucine Investigational, Nutraceutical Phase 4 61-90-5 6106
29
Baclofen Approved Phase 3 1134-47-0 2284
30
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
31
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
32
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
33
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
34
Ledipasvir Approved Phase 3 1256388-51-8 67505836
35
Sofosbuvir Approved Phase 3 1190307-88-0 45375808
36
Terlipressin Approved, Investigational Phase 3 14636-12-5 72081
37
Ethanol Approved Phase 3 64-17-5 702
38
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
39
tannic acid Approved Phase 3 1401-55-4
40
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
41
Iron Approved, Experimental Phase 3 7439-89-6, 15438-31-0 23925 27284
42 Antiviral Agents Phase 3
43 Antifungal Agents Phase 3
44 Immunosuppressive Agents Phase 3
45 Calcineurin Inhibitors Phase 3
46 Immunologic Factors Phase 3
47 Ledipasvir, sofosbuvir drug combination Phase 3
48 Nutrients Phase 3
49 Trace Elements Phase 3
50 Micronutrients Phase 3

Interventional clinical trials:

(show top 50) (show all 68)
# Name Status NCT ID Phase Drugs
1 Losartan in the Prevention of Sodium Retention and Ascites in Liver Cirrhosis – a Prospective Randomized Long-Term Study Unknown status NCT00239096 Phase 4 losartan (drug)
2 Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis- Child C: A Randomized Double Blind Control Trial Recruiting NCT03633279 Phase 4 Branched chain amino acid;Placebo
3 Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT02733809 Phase 4 Sorafenib
4 Hemodynamic Effects of Chronic Administration of Spironolactone, Propranolol and Their Association in Alcoholic Cirrhotic Patients Terminated NCT00188045 Phase 4 Propranolol - Spironolactone
5 Multicenter, Prospective, Open-label, Controlled, Randomized, Parallel Groups Study to Evaluate the Renal Function of Adult Liver Transplant Recipients Treated With Two Everolimus-based Immunosuppressive Regimens (Tacrolimus Withdrawal vs. Minimization) Until 12 Months Post-transplant, With a 6-months Follow-up Completed NCT02115113 Phase 3 Everolimus;Tacrolimus
6 Exploring the Efficacy and Biobehavioural Basis of Baclofen in the Treatment of Alcoholic Liver Disease Completed NCT01711125 Phase 3 Baclofen 30mg/day;Baclofen 75mg/day;Placebo
7 The Effects of Anti-Viral Therapy on the Clinical Status, Quality of Life, and Survival of Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection Completed NCT02597166 Phase 3 Ledipasvir/Sofosbuvir
8 Comparison of Bovine Colostrum Versus Placebo in Treatment of Severe Alcoholic Hepatitis: A Randomized Double Blind Controlled Trial Recruiting NCT02473341 Phase 3 Bovine Colostrum;Placebo
9 Multicentre, Randomised, Double-blind, Placebo-controlled Trial of Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence. Not yet recruiting NCT02824354 Phase 3 Nalmefene (Selincro®) 18 mg tablet;placebo
10 Influence of Iron Depletion by Phlebotomy on the Risk of Hepatocellular Carcinoma Occurrence in Patients With Compensated Alcoholic Cirrhosis. Prospective, Multicentre, Randomized Trial Terminated NCT01342705 Phase 3
11 International Randomized Study of Transarterial Chemoembolization Versus CyberKnife® for Recurrent Hepatocellular Carcinoma Withdrawn NCT01318200 Phase 3
12 The Evaluation of Effectiveness and Safety for New Therapy With Bone Marrow Derived Autologous Mesenchymal Stem Cell for Hepatic Failure Caused by Alcoholic Liver Cirrhosis Unknown status NCT01741090 Phase 2
13 Effects of Rifaximin Treatment in Patients With Acute Alcoholic Hepatitis: A Comparative Pilot Study Unknown status NCT02116556 Phase 2 Prednisone;Rifaximin
14 An Open-Label, Multi-Center, Single-Arm Study on Effectiveness and Safety of Stereotactic Body Radiotherapy (SBRT) Treating Hepatocellular Carcinoma Patients With CyberKnife Unknown status NCT02363218 Phase 2
15 A Parallel Group Randomized Open Blinded End Point Evaluation, Multicentric, Dose Escalation, Phase -II Study Assessing the Safety and Efficacy of Intraarterial (Hepatic) Ex-vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Alcoholic Liver Cirrhosis Completed NCT01591200 Phase 2
16 Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient. Completed NCT01875081 Phase 2
17 Maintaining Alcohol Abstinence in Alcoholic Patients With Liver Cirrhosis: Efficacy and Safety of Baclofen Administration in a Randomized Double Blind Controlled Study Completed NCT00525252 Phase 1, Phase 2 Baclofen;placebo
18 A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination With Prednisolone Versus Prednisolone Alone in Subjects With Severe Alcoholic Hepatitis (AH) Completed NCT02854631 Phase 2 Selonsertib;Prednisolone;Placebo
19 A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis Completed NCT00562783 Phase 2 Vitaliver;Placebo
20 Immune-inflammatory and Metabolic Effects of High Dose Furosemide Plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects With Refractory Ascite Completed NCT02821377 Phase 2 intravenous furosemide;Hypertonic saline solutions
21 Safety and Efficacy of Human Unbilical Cord Derived-mesenchymal Stem Cells Treatment for Patients With Decompensated Liver Cirrhosis Recruiting NCT03945487 Phase 2
22 Phase II Study of Combination Stereotactic Body Radiotherapy (SBRT) With Transarterial Chemo-Embolization (TACE) for Unresectable Hepatocellular Carcinoma Terminated NCT01020812 Phase 1, Phase 2
23 Treatment of Hepatic Encephalopathy With Benzodiazepine Antagonist (Flumazenil) and Change in Cortical GABA Levels in Localized 1H-MR Spectroscopy Withdrawn NCT02048969 Phase 1, Phase 2 Flumazenil;Placebo
24 Phase 1 Study of Intrahepatic Reinfusion of Highly Purified CD133+ Stem Cells in Patients With End-Stage Liver Disease Unknown status NCT01025622 Phase 1
25 Open Label, Study to Determine the Pharmacokinetic Interactions of Steady State Tipranavir/Ritonavir (500/200 mg) and Steady State Ribavirin and Pegylated Interferon Alfa 2a in HIV Negative, HCV Infected Subjects With Mild Hepatic Impairment and the Pharmacokinetic Properties of Tipranavir/Ritonavir in HIV Negative, HCV, HBV, Hepatitis Delta Infected Subjects or Alcoholic Cirrhosis Subjects With Moderate Hepatic Impairment Completed NCT02259855 Phase 1 Tipranavir;Ritonavir;Pegylated interferon;Ribavirin
26 Probiotic LGG in Patients With Minimal Hepatic Encephalopathy Completed NCT00992290 Phase 1
27 Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor: a Phase I Study Completed NCT00706576 Phase 1 Infusion of opioid growth factor
28 A Phase I, Open-Label, Single-Dose Study to Evaluate the Safety and Efficacy of Hepatic Artery Injection of Autologous Human Bone Marrow-Derived Mesenchymal Stem Cells (Cellgram™) in Patients With Alcoholic Liver Cirrhosis Recruiting NCT03838250 Phase 1
29 Genetical Predisposition in Hepatocellular Carcinoma : Pangenomic Link Study During Alcoholic Cirrhosis Unknown status NCT01065233
30 A Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Daily Oral Zinc Sulfate (220 mg) in Subjects With Alcoholic Cirrhosis Unknown status NCT02072746
31 Measurement of Fibrinogen in Patients With Systemic Inflammatory Response Syndrome, Sepsis, Chronicle Liver Disease or After Lysis on Intensive Care Units Unknown status NCT01169168
32 Is Access to Liver Transplantation Similar in Alcoholic or Not Patients? A Prospective Cohort Study Unknown status NCT01820819
33 Prospective Analysis Of Cardiac Function In Cirrhotic Patients By Echocardiography And Its Correlation With Adverse Events Unknown status NCT01433848
34 A Prospective Multicenter Study of Acute on Chronic Liver Failure in China Unknown status NCT02457637
35 Evolution of Nutritional Status, Metabolic, Functional and Clinical Outcomes in Patients Undergoing Liver Transplantation Unknown status NCT02917382
36 A Watermelon Focused Dietary Inflammatory Index Counseling System to Reduce Systemic Inflammation Unknown status NCT03158740
37 Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human : Study of Pro- and Anti-inflammatory Cytokines and ADIPOKINES.. Completed NCT00388323
38 Randomized Trial Comparing Liver Transplantation to Alternative Therapies for Patients With Pugh B Alcoholic Cirrhosis Completed NCT00701792
39 Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis in Addition to Prednisolon Therapy Completed NCT02326103 Early Phase 1 Ciprofloxacin;Placebo
40 Makuuchi Versus Barcelona Clinic of Liver Cancer Criteria in Cirrhotic Patients With Hepatocellular Carcinoma. Does Etiology of Cirrhosis Influence the Relationship Between the Portal Pressure and Quantitative Tests of Liver Function? Completed NCT00827723
41 Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound. Completed NCT01208311
42 Probiotic Modulation of Gut Microflora in Cirrhosis: Influence on Immune Function and Infections Completed NCT01607528
43 Impact of Alcohol Consumption of the General Population Who Visited Primary Health Care Centers on the Use of Health Care Resources in Catalonia. Completed NCT02343874
44 Metabolic and Nutritional Assessment in Patients on the Waiting List for Liver Transplantation Completed NCT01761851
45 Obesity - Inflammation - Metabolic Disease: Effect of Lactobacillus Casei Shirota Completed NCT01182844
46 Prognostic Value of Liver Volume on Acute Decompensation of Alcoholic Cirrhosis, a Prospective Multicenter Observational Study Recruiting NCT03508388
47 Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease Recruiting NCT04106518
48 A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area Recruiting NCT00913757
49 Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota - a Randomized Controlled Clinical Trial Recruiting NCT03863730
50 A Randomized, Pragmatic, Outcome-assessor-blinded Study of an SMS-message-based Lifestyle Intervention in Patients With Decompensated Liver Cirrhosis Recruiting NCT02811887

Search NIH Clinical Center for Alcoholic Liver Cirrhosis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Alcoholic Liver Cirrhosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Alcoholic Liver Cirrhosis:
Livercellgram, bone marrow-derived mesenchymal stem cells for treatment of alcoholic liver cirrhosis
Embryonic/Adult Cultured Cells Related to Alcoholic Liver Cirrhosis:
Bone marrow-derived mesenchymal stem cells

Cochrane evidence based reviews: liver cirrhosis, alcoholic

Genetic Tests for Alcoholic Liver Cirrhosis

Anatomical Context for Alcoholic Liver Cirrhosis

MalaCards organs/tissues related to Alcoholic Liver Cirrhosis:

40
Liver, Bone, Skin, Kidney, Testes, Heart, Monocytes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Alcoholic Liver Cirrhosis:
# Tissue Anatomical CompartmentCell Relevance
1 Liver Liver Lobule Hepatocytes Affected by disease

Publications for Alcoholic Liver Cirrhosis

Articles related to Alcoholic Liver Cirrhosis:

(show top 50) (show all 1345)
# Title Authors PMID Year
1
Association of polymorphism in alcohol dehydrogenase and interaction with other genetic risk factors with alcoholic liver cirrhosis. 54 61
20171022 2010
2
Polymorphism in cytochrome P450 2E1 and interaction with other genetic risk factors and susceptibility to alcoholic liver cirrhosis. 54 61
19428381 2009
3
Polymorphism in glutathione-S-transferases: a risk factor in alcoholic liver cirrhosis. 54 61
19157724 2009
4
Human serum fetuin A/alpha2HS-glycoprotein level is associated with long-term survival in patients with alcoholic liver cirrhosis, comparison with the Child-Pugh and MELD scores. 54 61
17394649 2007
5
[Serum cytokine concentration as prognostic factor in patients with alcoholic liver disease]. 54 61
17036498 2006
6
[Genetic polymorphisms of alcohol-metabolizing enzymes and cytokines in patients with alcohol induced pancreatitis and alcoholic liver cirrhosis]. 54 61
15220553 2004
7
New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. 54 61
14720455 2004
8
[Effects of genetic polymorphisms of ethanol-metabolizing enzymes on alcohol drinking behaviors]. 54 61
12824748 2003
9
[Studies on the mechanism of elevation of serum PIVKA-II levels in alcoholic liver cirrhosis]. 54 61
11985059 2002
10
Serum leptin levels in alcoholic liver cirrhosis: relationship with gender, nutritional status, liver function and energy metabolism. 54 61
11641747 2001
11
Hepatitis C and the leptin system: bound leptin levels are elevated in patients with hepatitis C and decrease during antiviral therapy. 54 61
11336170 2001
12
Serum cytokine levels in alcohol-related liver cirrhosis. 54 61
11282449 2001
13
Alcohol-related cirrhosis with pancreatitis. The role of oxidative stress in the progression of the disease. 54 61
11348018 2001
14
Serum levels of cytokines in alcoholic liver cirrhosis and pancreatitis. 54 61
11059648 2000
15
N-acetyltransferase-2, glutathione S-transferase M1, alcohol dehydrogenase, and cytochrome P450IIE1 genotypes in alcoholic liver cirrhosis: a case-control study. 54 61
10232877 1999
16
[Liver function and the level of total cholesterol in the blood serum in liver cirrhosis]. 54 61
10204356 1998
17
Oxidative stress in the liver and biliary tract diseases. 54 61
9867111 1998
18
Plasminogen in patients with liver cirrhosis. 54 61
9253235 1997
19
Plasma glutathione S-transferase alpha 1-1 levels in patients with chronic liver disorders. 54 61
9049444 1997
20
Polymorphisms in alcohol metabolizing enzyme genes and alcoholic cirrhosis in Japanese patients: a multivariate analysis. 54 61
7557863 1995
21
Altered expression of monocyte IgA Fc receptors is associated with defective endocytosis in patients with alcoholic cirrhosis. Potential role for IFN-gamma. 54 61
7636220 1995
22
Genotypes of alcohol-metabolizing enzymes in Mexicans with alcoholic liver cirrhosis. 54 61
8845660 1995
23
[Blood chemistry, hematology of patients with liver cirrhosis]. 54 61
8114309 1994
24
Erythrocyte antioxidant activity, serum ceruloplasmin, and trace element levels in subjects with alcoholic liver disease. 54 61
1575205 1992
25
[Membrane cholesterol and insulin receptor in erythrocytes]. 54 61
1774014 1991
26
Tissue-based miRNA mapping in alcoholic liver cirrhosis: different profiles in cirrhosis with or without hepatocellular carcinoma. 61
31701763 2020
27
Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study. 61
31062483 2020
28
Influence of diabetes mellitus on energy metabolism in patients with alcoholic liver cirrhosis. 61
31567641 2020
29
Serum levels of sclerostin reflect altered bone microarchitecture in patients with hepatic cirrhosis. 61
31912287 2020
30
Generation and characterization of three clones (NCCSi007A, NCCSi007B and NCCSi007C) of an integration free induced Pluripotent Stem Cell line from a patient with alcoholic liver cirrhosis of Indian ethnicity. 61
31862609 2020
31
RETROSPECTIVE ASSESSMENT OF CLINICAL-MORPHOLOGICAL CHANGES OF THE HEPATOBILIARY SYSTEM IN LIVER CIRRHOSIS OF THE CHORNOBYL NPP ACCIDENT CLEAN-UP WORKERS. 61
31841488 2019
32
Falling Rates of Hospital Admissions for Alcoholic Liver Disease in Northeast Italy: A Retrospective Study on a Large Database. 61
31566688 2019
33
Role of non-invasive markers in prediction of esophageal varices and variceal bleeding in patients of alcoholic liver cirrhosis from central India. 61
31854309 2019
34
Renal actinomycosis with retroperitoneal abscess in a cirrhotic patient: A case report (CARE-complaint). 61
31804331 2019
35
Risk factors for the concomitant occurrence of alcoholic chronic pancreatitis and alcoholic liver cirrhosis: a 10-years cohort study at a tertiary hospital in China. 61
31851081 2019
36
The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieu. 61
31637480 2019
37
O-GlcNAc transferase suppresses necroptosis and liver fibrosis. 61
31672932 2019
38
[A case of acute hyperammonemic encephalopathy with extensive cortical high-intensity lesions in diffusion weighted imaging]. 61
31564702 2019
39
Large Hepatic Artery Pseudoaneurysm Resection After Orthotopic Liver Transplantation. 61
31662581 2019
40
Alcohol and drug use prior to liver transplantation: more common than expected in patients with non-alcoholic liver disease. 61
31453745 2019
41
Physician Decision-Making Patterns and Family Presence: Cross-Sectional Online Survey Study in Japan. 61
31493327 2019
42
New Technique for Management of Separate Right Posterior and Anterior Portal Veins in Pure 3D Laparoscopic Living Donor Right Hepatectomy. 61
31485905 2019
43
Liver re-transplantation for donor-derived neuroendocrine tumor: A case report. 61
31616694 2019
44
Propofol pump controls nonconvulsive status epilepticus in a hepatic encephalopathy patient: A case report. 61
31616699 2019
45
Unilateral Pseudo-Ainhum in Liver Cirrhosis. 61
31850112 2019
46
[Liver transplantation: development, learning curve and results after the first 300 cases]. 61
31859959 2019
47
Intraabdominal Hemorrhage from Ruptured Ectopic Varices Treated by Antegrade Embolization via a Recanalized Paraumbilical Vein. 61
31073821 2019
48
Sepsis-related Organ Failure Assessment Score is a strong predictor of survival in acute-on-chronic liver failure. 61
31315795 2019
49
Right Heart Remodeling in Patients with End-Stage Alcoholic Liver Cirrhosis: Speckle Tracking Point of View. 61
31443575 2019
50
Number of hospital contacts with alcohol problems predicts later risk of alcoholic liver cirrhosis. 61
29528775 2019

Variations for Alcoholic Liver Cirrhosis

Expression for Alcoholic Liver Cirrhosis

Search GEO for disease gene expression data for Alcoholic Liver Cirrhosis.

Pathways for Alcoholic Liver Cirrhosis

Pathways related to Alcoholic Liver Cirrhosis according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.01 GSTM1 CYP2E1 CYP2A6 ALDH2 AKR1A1 ADH4
2
Show member pathways
12.53 GSTM1 CYP2E1 CYP2A6 ALDH2 ADH4 ADH1C
3
Show member pathways
12.47 ALDH2 AKR1A1 ADH4 ADH1C ADH1B
4
Show member pathways
12.18 TNF SOD2 F2 ALB
5
Show member pathways
11.66 CYP2A6 ALDH2 AKR1A1 ADH1B
6
Show member pathways
11.64 GSTM1 CYP2E1 CYP2A6
7
Show member pathways
11.61 ADH4 ADH1C ADH1B
8 11.51 TNF HGF CXCL8
9 11.49 PNPLA3 ALDH2 AKR1A1
10 11.35 TNF HGF CXCL8
11 11.28 F2 ALB AFP
12
Show member pathways
10.72 ALDH2 ADH4 ADH1B
13 10.69 ADH1C ADH1B
14
Show member pathways
10.67 CYP2E1 ALDH2 ADH1B
15 10.64 GSTM1 CYP2E1 CYP2A6 AKR1A1
16
Show member pathways
10.51 ALDH2 AKR1A1 ADH4 ADH1C ADH1B
17
Show member pathways
10.37 CYP2E1 CYP2A6 ADH1B
18 10.29 GSTM1 CYP2E1

GO Terms for Alcoholic Liver Cirrhosis

Cellular components related to Alcoholic Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood microparticle GO:0072562 9.46 TF F2 ALB AHSG
2 platelet alpha granule lumen GO:0031093 9.43 HGF ALB AHSG
3 endoplasmic reticulum lumen GO:0005788 9.35 TF F2 ALB AHSG AFP
4 extracellular space GO:0005615 9.32 TNF TF HGF GPT F2 CXCL8

Biological processes related to Alcoholic Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.63 TNF HGF F2
2 platelet degranulation GO:0002576 9.56 TF HGF ALB AHSG
3 oxidation-reduction process GO:0055114 9.56 SOD2 CYP2E1 CYP2A6 ALDH2 AKR1A1 ADH4
4 cellular protein metabolic process GO:0044267 9.55 TF F2 ALB AHSG AFP
5 retinol metabolic process GO:0042572 9.5 ADH4 ADH1C ADH1B
6 cellular aldehyde metabolic process GO:0006081 9.43 AKR1A1 ADH4
7 transport GO:0006810 9.4 ALB AFP
8 alcohol metabolic process GO:0006066 9.37 ALDH2 ADH4
9 ethanol oxidation GO:0006069 8.92 ALDH2 ADH4 ADH1C ADH1B

Molecular functions related to Alcoholic Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.56 SOD2 CYP2E1 CYP2A6 ALDH2 AKR1A1 ADH4
2 alcohol dehydrogenase activity, zinc-dependent GO:0004024 9.33 ADH4 ADH1C ADH1B
3 alditol:NADP+ 1-oxidoreductase activity GO:0004032 9.32 AKR1A1 ADH4
4 alcohol dehydrogenase (NAD) activity GO:0004022 9.26 ADH4 ADH1C
5 retinol dehydrogenase activity GO:0004745 8.92 AKR1A1 ADH4 ADH1C ADH1B

Sources for Alcoholic Liver Cirrhosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....